We are Azafaros

A beacon for people living with severe rare metabolic disorders.

A team of highly experienced industry experts

Azafaros is supported by a syndicate of leading Dutch and Swiss investors. Our clinical candidate AZ-3102 is an orally available azasugar designed to treat the central nervous system and to interfere with the metabolism of glycosphingolipids affecting key disease pathways through a unique dual mode of action.
Azafaros aims to be a beacon for patients living with severe rare genetic diseases and their families.

– Since 2018


Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress

BREAKING NEWS: Azafaros Receives FDA’s IND Clearance and Fast Track Designation